Ablavar Approval History
- FDA approved: Yes (First approved December 22nd, 2008)
- Brand name: Ablavar
- Generic name: gadofosveset trisodium
- Previous name: Vasovist
- Company: EPIX Pharmaceuticals, Inc.
- Treatment for: Diagnosis and Investigation
Ablavar - formerly Vasovist - (gadofosveset trisodium) is a blood pool magnetic resonance angiography (MRA) agent used to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
Development History and FDA Approval Process for Ablavar
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.